Literature DB >> 21985222

Modelling melanoma in mice.

Graeme J Walker1, H P Soyer, Tamara Terzian, Neil F Box.   

Abstract

Phenotypic and molecular heterogeneity in human melanoma has impaired efforts to explain many of the clinically important features of melanoma. For example, many of the underlying mechanisms that might predict age-of-onset, time to metastasis and other key elements in melanoma progression remain unknown. Furthermore, melanoma staging used to predict outcome and treatment has not yet moved beyond a basic phenotypic classification. While molecularly targeted therapies show great promise for melanoma patients, establishing accurate animal models that recapitulate human cutaneous melanoma progression remains a priority. We examine the relevance of mice as models for human melanoma progression and for key molecular and histopathologic variants of melanoma. These mice may be used as preclinical models to probe the relationships between causative mutations, disease progression and outcome for molecularly targeted therapeutics. We ask how new mouse models, or more detailed histopathologic and molecular analyses of existing mouse models, may be used to advance our understanding of genotype-phenotype correlations in this tumour type. This necessarily involves a consideration of the utility of mice as models for ultraviolet radiation-induced melanoma, and how this might be improved. 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2011        PMID: 21985222     DOI: 10.1111/j.1755-148X.2011.00923.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  15 in total

1.  Melanocyte transformation requires complete loss of all pocket protein function via a mechanism that mitigates the need for MAPK pathway activation.

Authors:  I D Tonks; P Mukhopadhyay; W A Schroder; A Sorolla; A W Mould; H Y Handoko; B Ferguson; H K Muller; P Keith; N K Hayward; G J Walker; G F Kay
Journal:  Oncogene       Date:  2017-02-13       Impact factor: 9.867

Review 2.  Conceptual approach to early melanoma detection: models, tools, issues and challenges.

Authors:  Shadi Damanpour; James M Grichnik
Journal:  Melanoma Manag       Date:  2015-11-24

Review 3.  Optimizing mouse models for precision cancer prevention.

Authors:  Clémentine Le Magnen; Aditya Dutta; Cory Abate-Shen
Journal:  Nat Rev Cancer       Date:  2016-02-19       Impact factor: 60.716

4.  Melanoma susceptibility as a complex trait: genetic variation controls all stages of tumor progression.

Authors:  B Ferguson; R Ram; H Y Handoko; P Mukhopadhyay; H K Muller; H P Soyer; G Morahan; G J Walker
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

5.  Transplantable malignant melanoma in LT.B6 congenic mice resembling pigmented epithelioid melanocytoma in humans.

Authors:  Soheil S Dadras; Kathleen A Silva; Lloyd E King; John P Sundberg
Journal:  J Invest Dermatol       Date:  2014-01-29       Impact factor: 8.551

6.  Animal models in retinoblastoma research.

Authors:  Rohini M Nair; Swathi Kaliki; Geeta K Vemuganti
Journal:  Saudi J Ophthalmol       Date:  2013-07

7.  Melanocyte Stem Cell Activation and Translocation Initiate Cutaneous Melanoma in Response to UV Exposure.

Authors:  Hyeongsun Moon; Leanne R Donahue; Eunju Choi; Philip O Scumpia; William E Lowry; Jennifer K Grenier; Jerry Zhu; Andrew C White
Journal:  Cell Stem Cell       Date:  2017-10-12       Impact factor: 24.633

Review 8.  Wnt/β-Catenin Signaling Pathway in Skin Carcinogenesis and Therapy.

Authors:  Jing Li; Ling Ji; Jieping Chen; Wengeng Zhang; Zhijia Ye
Journal:  Biomed Res Int       Date:  2015-05-19       Impact factor: 3.411

Review 9.  Current State of Animal (Mouse) Modeling in Melanoma Research.

Authors:  Omer F Kuzu; Felix D Nguyen; Mohammad A Noory; Arati Sharma
Journal:  Cancer Growth Metastasis       Date:  2015-10-06

10.  A Novel Fully Humanized 3D Skin Equivalent to Model Early Melanoma Invasion.

Authors:  David S Hill; Neil D P Robinson; Matthew P Caley; Mei Chen; Edel A O'Toole; Jane L Armstrong; Stefan Przyborski; Penny E Lovat
Journal:  Mol Cancer Ther       Date:  2015-09-01       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.